超声引导下微波消融联合贝伐珠单抗治疗晚期结肠癌伴肝转移的临床价值
Clinical value of ultrasound-guided microwave ablation combined with bevacizumab in the treatment of advanced colon adenocarcinoma with liver metastasis
韩小军 1袁理 2郭道宁1
作者信息
- 1. 621000 四川省绵阳市,电子科技大学医学院附属绵阳医院绵阳市中心医院超声医学科
- 2. 621000 四川省绵阳市,电子科技大学医学院附属绵阳医院绵阳市中心医院肿瘤科
- 折叠
摘要
目的 探讨超声引导下微波消融联合贝伐珠单抗治疗晚期结肠癌伴肝转移的临床应用价值.方法 选取在我院就诊的102例晚期结肠癌伴肝转移患者,按随机数字表法分为观察组和对照组各51例,对照组采用贝伐珠单抗联合常规化疗治疗,观察组在此基础上采用超声引导下微波消融治疗;比较两组患者治疗后疗效、免疫功能、不良反应及预后情况.结果 治疗后,观察组客观缓解率(ORR)、疾病控制率(DCR)均高于对照组(均P<0.05);两组CD3+、CD4+、CD8+均较治疗前下降,且观察组CD3+、CD4+、CD4+/CD8+均高于对照组,CD8+低于对照组,差异均有统计学意义(均P<0.05).治疗后,两组胃肠道反应、食欲减退、疲劳乏力等不良反应比较差异均无统计学意义;观察组累积无复发生存率及累积总生存率分别为78.77%、57.45%,均高于对照组(49.32%、34.23%),差异均有统计学意义(χ2=10.086、4.536,P=0.001、0.033).结论 超声引导下微波消融联合贝伐珠单抗能提高晚期结肠癌伴肝转移患者的治疗效果,缓解免疫功能抑制,改善生存状况,具有较好的临床应用价值.
Abstract
Objective To explore the application clinical value of ultrasound-guided microwave ablation combined with bevacizumab in the treatment of advanced colon adenocarcinoma(COAD)with liver metastasis.Methods A total of 102 patients with advanced COAD with liver metastasis treated in our hospital were selected,and divided into the observation group and the control group by random number table method,with 51 cases in each group.The control group was treated with bevacizumab combined with conventional chemotherapy.On this basis,the observation group was treated with ultrasound-guided microwave thermal ablation.The curative effect,immune function,adverse reactions and prognosis after treatment of the two groups were compared.Results After treatment,the objective remission rate(ORR)and disease control rate(DCR)in the observation group were higher than those in the control group(both P<0.05).After treatment,the CD3+,CD4+ and CD4/CD8+ in the observation group were higher than those in the control group,and CD8+ was lower than that in the control group,the differences were statistically significant(all P<0.05).After treatment,there were no statistically significant difference in the incidence rates of adverse reactions such as gastrointestinal reactions,loss of appetite and fatigue between the two groups.The cumulative recurrence-free survival rate and cumulative overall survival rate in observation group were 78.77%and 57.45%respectively,which were significantly higher than those in control group(49.32%and 34.23%),the differences were statistically significant(χ2=10.086,4.536,P=0.001,0.033).Conclusion Ultrasound-guided microwave ablation combined with bevacizumab can effectively improve the curative effect,relieve immune suppression and improve survival status of patients with advanced COAD with liver metastasis,which has a good clinical application value.
关键词
超声引导/微波消融/结肠癌,晚期/肝转移/贝伐珠单抗Key words
Ultrasound-guided/Microwave ablation/Colon adenocarcinoma,advanced stage/Liver metastasis/Bevacizumab引用本文复制引用
出版年
2024
NETL
NSTL
万方数据